Open Access Repository

Intravenous bisphosphonates do not improve knee pain or bone marrow lesions in people with knee osteoarthritis: a meta-analysis

Zhang, X, Cai, G, Jones, G ORCID: 0000-0002-9814-0006 and Laslett, LL ORCID: 0000-0002-4336-0095 2021 , 'Intravenous bisphosphonates do not improve knee pain or bone marrow lesions in people with knee osteoarthritis: a meta-analysis' , Rheumatology , doi: 10.1093/rheumatology/keab786.

Full text not available from this repository.

Abstract

Objective:To summarise effects of intravenous bisphosphonates (IVBP) in patients with symptomatic knee osteoarthritis (OA) and bone marrow lesions (BMLs), using a meta-analysis of randomized controlled trials (RCTs).Methods:Literature databases were searched for placebo-controlled RCTs of IVBPs for knee OA from inception, and included validated pain and function scales, BML size, and incidence of adverse events. Efficacy was compared using standardized mean differences (SMD) and risk ratios (RR) with fixed-effect or random-effects models. Methodological quality was assessed using the Cochrane risk of bias tool, heterogeneity was assessed by I2 statistics.Results:We included 428 patients in 4 RCTs of 2–24 months duration; most patients (84%) received zoledronic acid (ZA). Risk of bias was low-moderate. IVBP had large effect sizes on pain within 3 months (SMD= -2.33 (95% confidence interval= -3.02, -1.65)) mainly driven by neridronate (resulting in substantial heterogeneity, I2=92%) with no effect for ZA alone. Differences in knee function were statistically significant at 3 months (SMD=-0.22 (-0.43, -0.01), I2=0.2%). Effect sizes for pain did not reach statistical significance at any other time point. IVBPs improved a semi-quantitative measure of BML size within 6 months (SMD= -0.52 (-0.89, -0.14), I2=0%) but not at 12 months or two years. Adverse events (RR = 1.19 (1.00, 1.41) I2=52%), occurred more frequently with IVBP.Conclusion:ZA has no effect on knee pain, possibly a short-term effect on BML size and higher rates of adverse events. Neridronate may improve pain in the short term, but this is based on a single trial.

Item Type: Article
Authors/Creators:Zhang, X and Cai, G and Jones, G and Laslett, LL
Keywords: bisphosphonates, knee, osteoarthritis, pain, trial, meta-analysis
Journal or Publication Title: Rheumatology
Publisher: S. Karger AG
ISSN: 0080-2727
DOI / ID Number: 10.1093/rheumatology/keab786
Copyright Information:

Copyright 2021 The Authors

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP